Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2017-07-01 Director's Dealing
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2017-07-01 English
FORM 4 -
Director's Dealing
2017-07-01 English
FORM 4 -
Director's Dealing
2017-06-30 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 20, 2017, by Madrigal Pharmaceuticals, Inc. It reports the entry into a material definitive agreement related to a securities purchase agreement and a private placement offering of common stock and Series A Convertible Preferred Stock. It also includes details about the registration rights agreement, unregistered sale of equity securities, amendments to articles of incorporation related to the preferred stock, and a press release announcing the offering. The content focuses on financing activities, specifically a private placement and related agreements. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, management report, or governance information. The primary subject is the company's capital raising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing transaction, not just an announcement or reference to a report, so it is not RPA or RNS.
2017-06-21 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text describes an update on a clinical trial progress and a recommendation from the Data and Safety Monitoring Committee (DSMC) to continue the trial without changes. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is an event update about clinical trial progress, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories. The document length is 3628 characters, which is relatively short and consistent with an 8-K event report rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-06-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2017, by Madrigal Pharmaceuticals, Inc. It specifically reports "Results of Operations and Financial Condition" for the first fiscal quarter ended March 31, 2017. The document includes a press release announcing financial results, which is furnished as an exhibit. The text states that the press release is incorporated by reference and is not deemed filed for certain regulatory purposes. The document length is 3646 characters, which is relatively short and primarily serves as an announcement of financial results rather than a full financial report. According to the SEC filing types and the provided classification rules, a Form 8-K reporting quarterly financial results is best classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights, not a comprehensive interim report (IR) or annual report (10-K).
2017-05-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.